Prospective 7-year monitoring of MAC bacteremia in HIV-positive Swedish patients  by Julander, Inger et al.
ORIGINAL ARTICLE 
Prospective 7-year monitoring of MAC bacteremia in 
HIV-positive Swedish patients 
Ingerlulander I ,  Sven Hoffne?, Gunilla Kallenius ' I ,  Lennart Ostlund and 
Bjorn Petrini 
'Department of Immunology, Microbiology, Pathology and Infectious Diseases, Division of 
Infectious Diseases, Karolinska Institute, Huddinge Hospital, 'Microbiology Tumor Biology Center, 
Karolinska Institute, 3Department of Infectious Diseases, Danderyd Hospital, Karolinska Institute, 
and 4Department of Clinical Microbiology, Karolinska Institute and Hospital, Stockholm, Sweden 
Objective: To record the cumulative incidence of Mycobacterium avium complex (MAC) bacteremia among HIV- 
infected patients and to study colonization in relation to symptoms of infection. 
Methods: In a prospective study, 61 patients with a CD4 count c20Ox1O6/L were followed by cultures from sputum, 
feces and blood every 3-6 months and for development of MAC bacteremia and clinical symptoms. The main end-points 
were MAC bacteremia and death. 
Results: From the start in November 1989 to January 1997 about 34% had developed MAC bacteremia with a median 
follow-up of 22 months. At the time of positive blood cultures, all but one patient had symptoms consistent with 
disseminated MAC infection. Positive cultures from respiratory and gastrointestinal tract were recorded before MAC 
bacteremia in only four patients. All but one had symptoms at the time of positive blood culture. 
Conclusions: The incidence of MAC bacteremia was similar to figures in other studies. The presence of symptoms in 
close relation to positive blood cultures supports late colonization and late infection in HIV disease. Screening patients 
with samples from the respiratory and gastrointestinal tracts is not uiseful 
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INTRODUCTION 
Mycobacterium avium complex (MAC) is present in the 
general surroundings, e.g. in water, food and soil. MAC 
can cause Merent kinds of diseases: pulmonary disease 
with and without a pre-existing pulmonary condition, 
lymphadenitis in children, and disseminated infection 
in HIV-infected patients. In the last group, the cumu- 
lative incidence of mycobacteremia varies between 
15% and 60%, (1-61. However, the epidemiology, 
pathogenesis and presence of carriership in relation to 
clinical symptoms are not fully understood. 
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The aims of the present study were to record 
the cumulative incidence of MAC bacteremia and 
coloniz.ation as measured by cultures from the upper 
respiratory and gastrointestinal tracts, and to relate 
positive cultures to clinical symptoms. The main end- 
points 'were death and MAC bacteremia. 
We found that MAC could only be isolated 
from patients with severe immunodeficiency and that 
positive blood cultures were strongly correlated with 
the presence of symptoms. The cumulative incidence 
was 34%. 
PATIENTS AND METHODS 
In a pnxpective study from November 1989 to March 
1990 .at the Departments of Infectious Diseases, 
Roslagstull/Huddinge and Danderyd Hospitals, con- 
secutive HIV-positive patients with at least one CD4 
count d 200 x 1 06/L were asked to participate. Sixty- 
six patients were enrolled, but five dropped out. Of 
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the remaining 57 men and four women, 50 were 
homo/bisexual men, two had been heterosexually 
infected, seven were intravenous drug addicts and 
two had been infected by blood products. Among the 
patients, 43 were born in Sweden, 14 in other parts 
of Europe, two in the USA, one in Africa and one 
in Thailand. The great majority (43/61) were aware of 
BCG vaccination. The median age was 37 (22-73) 
years. At enrollment, 20 were classified as AIDS/ 
opportunistic infections (1 7 pneumocystis carinii pneu- 
monia (PCP), one cytomegalovirus infection (CMV), 
one as toxoplasmosis, one as candida esophagitis, 
and one as AIIlS/Kaposi's sarcoma). Prophylaxis against 
MAC or tuberculosis had not been given. 
This cohort of patients was followed by cultures 
from blood, feces and sputum every 3-6 months. For 
a total of 420 visits seven blood, 86 fecal and 126 
sputum specimens were not received. Blood was 
cultured in BACTEC 13 A broth, and feces and sputum 
on Liiwenstein-Jensen medium. 
The following data were recorded: initial CD4 
count, results of cultures, presence of clinical symptoms 
like cough. diarrhea (four or more stools per day), fever 
(>38"C at least twice in the last months), anti-HIV 
therapy, time of follow-up, interval between inclusion 
and death/positive culture, survival in MAC-positive 
(MAC bacteremia) and MAC-negative patients, and 
detection time of MAC isolates. Kaplan-Meier analysis 
was used to compare survival between groups. 
MAC was identified by DNA hybridization using 
the Accu-Probe MAC culture identification test (Gene- 
Probe, San Iliego, CA, USA). Individual species of 
M .  aviuin and M .  intracellulare were not identified. 
Llecontamination of specimens was performed by 
addition of 3 mL of 1% NaOH and 3% sodium lauryl 
sulfate to 1 mL of sputum or feces and shaking for 
30 min. 
RESULTS 
All baseline cultures were negative. The initial CD4 
count varied from 200 to 2X1O6/L. In 14 patients, 
CD4 count was determined at inclusion, in 34 within 
3 months from inclusion, and in the remaining 13, 
4-1 4 months before inclusion. The median number of 
follow-up visits was six (2-33). By January 1997, 54 of 
the patients had died and seven were alive. Among the 
dead patients, 21 of 54 (39%) had developed MAC 
bacteremia, and when all patients were included, the 
figure was 21 of 61 (34.4%). The cumulative incidence 
was in 1990, 18%; 1991, 30%; 1992 and 3993, 33%; 
1994 and 1995, 34%. 
Two patients had bacteremia caused by niyco- 
Table 1 Number of first MAC-positive sites and final 
number of MAC-positive sites in each patient with MAC 
bacteremia 
Sites 
Sites of Sites of 
first positivc culture 
(number of patients) 
final positivc culture 
(number of patients) 
Blood only 7 
Blood + sputum 3 
Blood + feces + cputuin 
Blood + feces 3 
3 
3 
5 
3 
1 0  
bacteria other than MAC: an unidentifiable strain in 
one ca$e and A4. siminae in one. These two patients 
were not included in the total of 21 with MAC 
bacteremia. Among patients with negative blood 
cultures, MAC was isolated from sputum only in one 
and from feces only in two. First positive cultures and 
subsequent positive cultures are given in Table 1. 
The median detection time for blood isolates 
was 27 (15-73) days. Positive feces culture preceded 
bacteremia only by 2 months in one patient and by 10 
months in another. Sputum culture was positive 3 
months before bacteremia in one patient and 2 months 
before bacteremia in another. 
All but one patient had symptoms at the time of 
positive blood culture: fever in six, fever and diarrhea 
in six, diarrhea only in two, fever, diarrhea and cough 
in two, and fever and cough in four. The patients 
asymptomatic at the time of positive culture from 
blood, sputum and feces developed fever after about 45 
days. 
Statistical data for time intervals between inclusion 
and positive cultures and survival, respectively, in 
different groups are given in Table 2. Survival was 
somewhat shorter in patients with MAC bacteremia 
than in the others (Kaplan-Meier analysis not signi- 
ficant) and there was great variation with regard to 
survival among patients with MAC bacteremia. When 
the initial CD4 counts in the dead patients were 
considered, there was no difference between patients 
with and without MAC (data not shown). Of the 
patients with bacteremia, 1 1  of 21 had an AIDS 
diagnosis before inclusion. However, when the seven 
patients still alive were taken into account, it was found 
that they had a higher initial CD4 count (90-200) than 
the others. This is probably the main reason for longer 
survival. These patients had all survived long enough to 
benefit from protease inhibitors. Differences in the time 
of enrollment could not be an explanation, as the study 
patients were recruited within a period of 3 months. 
Of  the 21 patients with MAC bacterenlla, all 
but three were given antimycobacterial treatment with 
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Table 2 Statistical data in 61 patients followed for MAC bacteremia 
~~~ ~~ 
Intervals Number of patients Median (range) 
Inclusion to follow-up 61 18 (3-74) months 
Survival MAC positive (blood) 21 12 (3-49) months 
Survival MAC neganve (blood) 32 16 (4-74) months 
Positive culture to death 21 5.5 (0.5-40) months 
Inclusion to positive culture (blood) 21 12 (3-37) days 
ethambutol, rifabutin and amikacin, with a median 
duration of 5 (0.5-2) months. 
During thrs long study period, the patients received 
different regimens and most of them participated in 
studies. The seven patients who were alive at termina- 
tion of the study had lived long enough to receive 
protease inhibitors, whereas all dead patients but two 
had taken zidovudine alone or with either ddl, ddC, 
stavudine or 3 TC. Some of the patients had also been 
treated with interferon, Peptide T and isoprinosine in 
studies. 
DISCUSSION 
MAC commonly causes disseminated infection in 
HIV patients. In studies from the USA, the reported 
cumulative incidence has varied between 20% and 40%. 
A similar incidence (34%) was recorded in our study. 
However, the design of these studies differed [l-31. To 
our knowledge, cumulative incidence figures from 
countries in Europe have not been published with a 
long follow-up. When our investigation was started in 
1989, it was not well-known that disseminated MAC 
infection (DMAC) develops only in patients with a 
CD4 count < 100X1O6/L. Therefore, the inclusion 
criterion was set at CD4 S200~10'/L. The knowledge 
of pathogenesis of DMAC has increased in recent years, 
but there are still some unanswered questions. It has 
been unclear whether DMAC is a reactivated infection 
or if there is a late colonization closely followed by 
MAC bacteremia. 
Strong evidence exists for the late development 
of DMAC, as there is no difference in incidence in 
relation to age, sex, gender, risk group or origin [ 3 ] .  
The prevalence of sensitin skin reactivity in a North 
American population is lower than the incidence of 
MAC bacteremia [4]. Further evidence for this is 
provided by the present study and the study by Havlik 
et al [l], where positive cultures were closely related to 
symptoms. In contrast, it was reported by Chin et a1 
[3] that positive cultures from feces and sputum did 
precede MAC bacteremia, with a few exceptions. More 
support for late colonization was provided by von Reyn 
et a1 [7] ,  who found that the source of MAC in an 
outbreak was hot water, with the same strain cultured 
from the blood of the patients. Prediction of MAC 
bacterernia would be desirable, but data from our study 
do not support monitoring of patients by screening 
samples from respiratory and gastrointestinal tracts, 
since the interval from such positive samples until 
bacteremia is very short. Another fact which must be 
considered is the possibility of concomitant existence 
of different strains in specimens horn different sites 
in the same patient, as found in a study of ours [ 8 ] .  
Different MAC serovars have also been found on 
different occasions [8]. 
The gastrointestinal tract is believed to be the main 
portal of entry for DMAC infection. In the present 
study, IMAC could often be isolated from both sputum 
and fecal specimens. The respiratory tract is also a 
possible portal of entry. Particles of water containing 
MAC &om the hot water system can, for example, be 
inhaled from showers [7]. In the present study it is 
difficult to exclude the possibility that sputum was 
contaminated by saliva which can be colonized by 
MAC and swallowed. Not unexpectedly, some patients 
could not produce any sputum samples. 
In the present study the effect of treatment on 
survival could not be evaluated, since most of the 
patients had been treated with antimycobacterial drugs. 
In other studies the prognosis was better in patients 
with negative than positive MAC cultures [9]. There 
was also such a trend in the present study. It has not 
been proved that the frequency of MAC bacteremia is 
increasing, although diagnostic methods have probably 
improvNed over the years, and prolonged survival in 
AIDS patients with severe immunosuppression would 
facilitate such infection. Early recognition of symptoms 
consisttmt with MAC bacteremia, and early diagnosis 
and treatment, could improve the prognosis and reduce 
symptoms in these patients. 
The influence of antiretroviral therapy on develop- 
ment ofMAC bacteremia could not be evaluated in this 
study. 
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